Implication of the new low-density lipoprotein goals in dyslipidemia management of patients with acute coronary syndrome

Mayo Clinic Proceedings

Volumn 82, Issue 5, 2007, Pages 551-555

  Kontos, Michael C ^a,b   Joyner, Sarah E ^a   Roberts, Charlotte S ^a   Anderson, F Philip ^b   Ornato, Joseph P ^a   Tatum, James L ^b   Jesse, Robert L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE CLASSIFICATION; DRUG DOSE COMPARISON; DYSLIPIDEMIA; FEMALE; HEART INFARCTION; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT;

EID: 34248228864     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.5.551     Document Type: Article

References (20)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
2. LaRosa JC, Grundy SM, Waters DD, et al, Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 Apr 7;352:1425-1435. Epub 2005 Mar 8.
3. Cannon CP, Braunwald E, McCabe CH, et al, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive and moderate lipid lowering with statins after acute coronary syndromes [published correction appears in N Engl J Med. 2006; 354:778]. N Engl J Med. 2004;350:1495-1504.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
5. Grundy SM, Cleeman JI, Merz CN, et al, Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol. 2004;44:720-732.
6. Jackson R, Scragg R, Marshall R, White H, O'Brien K, Small C. Changes in serum lipid concentrations during first 24 hours after myocardial infarction. Br Med J (Clin Res Ed). 1987;294:1588-1589.
7. Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol. 1993;22:933-940.
8. Tatum JL, Jesse RL, Kontos MC, et al. Comprehensive strategy for the evaluation and triage of the chest pain patient. Ann Emerg Med. 1997;29:116-125.
9. Alpert JS, Thygesen K, Bassand JP, Bassand JP. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction [published correction appears in J Am Coll Cardiol. 2001; 37:973]. J Am Coll Cardiol. 2000;36:959-969.
10. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs [editorial]. Am J Cardiol. 1997;80:106-107.
11. Shepherd J, Cobbe SM, Ford I, et al, West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
12. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-1389.
13. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
14. Sacks FM, Pfeffer MA, Moye LA, et al, Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
15. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction) [published correction appears in J Am Coll Cardiol. 2005;45:1376]. J Am Coll Cardiol. 2004;44:671-719.
16. Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol. 2003;92(4B):23K-29K.
17. Jones PH, Davidson MH, Stein EA, et al, STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-160.
18. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004;93:1487-1494.
19. Ballantyne CM, Houri J, Notarbartolo A, etal, Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003 May 20;107:2409-2415. Epub 2003 Apr 28.
20. Nam BH, Kannel WB, D'Agostino RB. Search for an optimal atherogenic lipid profile: from the Framingham Study. Am J Cardiol. 2006;97:372-375.